Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) reports progress on its antiviral candidate, ensovibep, designed to combat SARS-CoV-2. It retains full potency against all known variants, including Delta. The EMPATHY Phase 2/3 trial is enrolling patients across 5 countries, with expansion planned. The ACTIV-3 trial for hospitalized patients is actively recruiting. A subcutaneous formulation is set for clinical trials in H2 2021. Ensovibep shows potential for differentiated treatment amid mixed vaccination rates globally.